BidaskClub upgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a strong sell rating to a sell rating in a research note issued to investors on Saturday morning.
Several other equities research analysts have also weighed in on PRTK. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a hold rating to a buy rating and set a $21.00 target price on the stock in a report on Wednesday, January 10th. Leerink Swann reiterated an outperform rating on shares of Paratek Pharmaceuticals in a report on Sunday, March 4th. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the stock a buy rating in a report on Thursday, April 5th. Raymond James Financial reiterated an outperform rating and issued a $36.00 target price on shares of Paratek Pharmaceuticals in a report on Friday, March 2nd. Finally, UBS lowered shares of Paratek Pharmaceuticals from a strong-buy rating to an outperform rating in a report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $40.00.
PRTK opened at $13.35 on Friday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $437.06, a price-to-earnings ratio of -4.05 and a beta of 0.43. Paratek Pharmaceuticals has a twelve month low of $11.85 and a twelve month high of $29.00.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.03). The firm had revenue of $5.07 million during the quarter, compared to analyst estimates of $5.00 million. Paratek Pharmaceuticals had a negative return on equity of 93.16% and a negative net margin of 706.00%. research analysts predict that Paratek Pharmaceuticals will post -3.44 earnings per share for the current year.
In related news, Director Robert S. Radie sold 3,000 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $14.22, for a total transaction of $42,660.00. Following the sale, the director now directly owns 9,330 shares in the company, valued at $132,672.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Douglas W. Pagan sold 5,237 shares of the firm’s stock in a transaction on Monday, April 9th. The stock was sold at an average price of $12.70, for a total transaction of $66,509.90. Following the sale, the chief financial officer now owns 77,083 shares in the company, valued at $978,954.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 68,385 shares of company stock worth $925,282. 4.90% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the stock. Great West Life Assurance Co. Can acquired a new stake in shares of Paratek Pharmaceuticals during the third quarter worth $104,000. SG Americas Securities LLC acquired a new stake in Paratek Pharmaceuticals in the 3rd quarter valued at $123,000. MetLife Investment Advisors LLC acquired a new stake in Paratek Pharmaceuticals in the 4th quarter valued at $185,000. Landscape Capital Management L.L.C. acquired a new stake in Paratek Pharmaceuticals in the 4th quarter valued at $221,000. Finally, Belpointe Asset Management LLC acquired a new stake in Paratek Pharmaceuticals in the 3rd quarter valued at $228,000. Institutional investors and hedge funds own 74.44% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Paratek Pharmaceuticals (PRTK) Raised to Sell at BidaskClub” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/17/paratek-pharmaceuticals-prtk-raised-to-sell-at-bidaskclub.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.